Oh c'mon, near-perfect assembly is not the same as near perfect read. If you don't know that you have no business owning PACB. This type of claims is what turned off people from PACB early on, and they had to work really hard for a few years to dig themselves out from under that mud.
$700M tool requiring reinforced floor and specialized facilities to run vs. a laptop instrument? Plus, they are not abandoning one, merely spreading their bets. PACB gets them something today (assuming they release their rumored desktop instrument), Genia covers them for the future.
Except that if Genia works it will put PACB out of business. Yeah, yeah, bird in hand vs. two in the bush... Roche is doing the right thing and moving to where the game may be 3-5 years from now. They already #$%$ away $60M+ on IBM and got exactly zero bases of readout to show for it. At least they are now buying something that has at least been shown to do some sequencing.
Of all companies in this field PACB is most susceptible to disruption. Most of the contenders can't touch Illumina on accuracy and throughput and will be unable to do so for years to come (which does not mean that Illumina's position is assured). However, all of them clamor to do what PACB is doing (long reads, low accuracy) at a fraction of the capex. Heck, the minion is practically free in comparison to a RS2. If any of them work out PACB is toast. The minion is already showing 8k+ reads with 60-ish percent accuracy. Can't do real sequencing, but bacterial genome scaffolding is completely within reach. And that is precisely the market that PACB plays in... the only market they play in.
Well we just bounced off our 200 day MA twice in the last 24 hours. I'm confident in saying that we are now on our way to higher gains people.
Sentiment: Strong Buy
Why would Roche buy PACB when they already have an iron clad deal in writing with them giving them exclusive rights to PACB technology for cancer diagnostics applications, and they paid peanuts for it?
"Their technology is interesting in that it uses both a biological nanopore and a polymerase. The polymerase sits atop the nanopore, and a template single molecule of DNA is provided to the polymerase. Single nucleotides are added to the mix and each nucleotide has a “NanoTag” tail. As the polymerase incorporates the nucleotides, the nanopore sucks in the NanoTag, and this event is measured electronically. The polymerase moves on and the nanopore measures the next base etc etc. " "Any guidance on the limits on measurement performance in terms of bases per second? 10bps wouldn’t be practical for anything but small viruses. This is quotes from experts in the field,such Mick Watson!
It would seem there is another offer on the table for PACB with a different company. That could be your answer.
This was a bit of a shocker for me as why would Roche buy Genia instead of PACB with whom they already of a contract with. Here is the write up on Genia:
Genia Technologies, Inc. is a privately held company located in Mountain View, CA. Founded in March 2009, Genia is developing a potentially disruptive next generation sequencing technology with integrated circuits enabling massively parallel, single-molecule DNA sequencing. Its versatile nanopore-based platform allows for single molecule, electrical real-time analysis without the need for complicated optics, labels, amplification, or fluidics. The heart of Genia’s technology is a semiconductor integrated circuit where an automated assembly of nanopores in a lipid bilayer allows for the measurement of single molecules. Genia’s sensor technology and its proprietary NanoTag chemistry enables accurate base calls, overcoming many of the limitations faced by other nanopore-based sequencing efforts.
Looks like we may test that 200 day MA again real soon. Like I said before. Tomorrow has huge potential if we hold our gains today.
There was not enough volume nor accumulation above the 200 day MA. Plain and simple. It's not BS its the technicals and fundamentals of all stocks. The 200 day MA is out ceiling. If we break through it with enough volume it then becomes a floor. Haven't you read any investing books? I feel like this is amature hour over here. We will test the 200 MA again soon. It won't last forever. Be patient PACB is a great biotech and more news will soon surface on its performance.
Sentiment: Strong Buy
theory is BS. Head and shoulders, candlesticks, moving averages, etc etc etc etc., are useless overrrated theories that are garbage. Especially when attempting to use them as they apply to biotech.
5/29/2014 Near perfect de novo assemblies of eukaryotic
genomes using PacBio long read sequencing! (for link go to IHUB PACB M B)